Iowa State Bank Has $1.43 Million Holdings in Cencora, Inc. (NYSE:COR)

Iowa State Bank grew its stake in Cencora, Inc. (NYSE:COR) by 3.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 6,375 shares of the company’s stock after buying an additional 198 shares during the period. Iowa State Bank’s holdings in Cencora were worth $1,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of COR. Arizona State Retirement System boosted its stake in Cencora by 6.3% during the second quarter. Arizona State Retirement System now owns 52,047 shares of the company’s stock worth $11,726,000 after buying an additional 3,089 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of Cencora by 11.5% during the 2nd quarter. Private Advisor Group LLC now owns 6,785 shares of the company’s stock valued at $1,529,000 after acquiring an additional 700 shares in the last quarter. Candriam S.C.A. increased its stake in Cencora by 21.9% in the second quarter. Candriam S.C.A. now owns 7,897 shares of the company’s stock valued at $1,779,000 after acquiring an additional 1,420 shares during the period. Savant Capital LLC raised its position in Cencora by 2.1% in the second quarter. Savant Capital LLC now owns 6,511 shares of the company’s stock worth $1,467,000 after purchasing an additional 132 shares in the last quarter. Finally, SRS Capital Advisors Inc. lifted its stake in Cencora by 6.7% during the second quarter. SRS Capital Advisors Inc. now owns 3,338 shares of the company’s stock worth $752,000 after purchasing an additional 210 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 94,696 shares of company stock valued at $22,862,734. 15.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company lowered their price objective on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. Evercore ISI increased their price objective on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Trading Up 0.1 %

Shares of COR traded up $0.15 during trading hours on Monday, hitting $229.35. 361,763 shares of the stock traded hands, compared to its average volume of 930,216. The business has a fifty day moving average of $237.44 and a 200-day moving average of $233.60. The firm has a market capitalization of $44.33 billion, a PE ratio of 30.54, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45. Cencora, Inc. has a 1-year low of $208.58 and a 1-year high of $253.27. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.96%. Cencora’s dividend payout ratio is presently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.